
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 30 years ago
Goals and Objectivesover 30 years ago
Promoting Smoking Cessation in a Managed Care Environmentover 30 years ago
Smoking Cessation Benefitsover 30 years ago
Characteristics of Successful Interventionover 30 years ago
Quitting & Starting: Advice on Both from Guideline Expertover 30 years ago
CME Quizover 30 years ago
Participants





